IP Explained: Why patents are so critical to biopharmaceutical innovation
By Tom Wilbur | April 16, 2019
Today, we are excited to launch our new IP Explained Catalyst series, where each week we’ll break down critical components of the intellectual property (IP) system and the important role it plays...
Read More
Minority health matters
By Courtney Christian | April 15, 2019
April is National Minority Health Month, a time to recognize and raise awareness of health disparities that affect racial and ethnic minorities.
Read More
Six policy solutions to help patients afford their insulin
By Holly Campbell | April 9, 2019
Dramatic improvements in how we treat diabetes have transformed the lives of patients, but too many struggle to afford their insulin and other medicines at the pharmacy counter. Due to...
Read More
PhRMA comments on OIG proposed rule to reform the rebate system
By Holly Campbell | April 8, 2019
Today, PhRMA submitted comments on the Department of Health & Human Services (HHS) Office of Inspector General (OIG) proposed rule, “Removal of Safe Harbor Protection for Rebates Involving...
Read More
340B continues to drive shift in site of care for physician-administered medicines to more expensive hospital settings
By Nicole Longo | April 5, 2019
Is 340B benefiting the vulnerable, uninsured patients it was designed to help? Evidence continues to show otherwise. An updated analysis from Berkeley Research Group (BRG) is the latest to build...
Read More
New report shows nearly 20 innovative medicines in development for sickle cell disease
By Andrew Powaleny | April 2, 2019
Sickle cell disease (SCD) is the most common inherited blood disorder in the United States, afflicting nearly 100,000 Americans. Patients with SCD have sickle-shaped red blood cells, which have...
Read More
Five key facts about the market for insulins
By Holly Campbell | April 1, 2019
A century ago, patients were treated with animal insulins. Today, biopharmaceutical companies produce insulins that operate at the molecular level, more closely resembling insulin released...
Read More
If the six protected classes policy is weakened, the Medicare Part D exception and appeals process will not provide sufficient protections for patients facing access challenges
By Tom Wilbur | March 29, 2019
One of the most important and successful parts of Medicare Part D is the six protected classes policy which covers patients whose conditions – such as HIV, cancer, and epilepsy, among others – are...
Read More
Fact Check: How the Part B International Pricing Index model threatens patient access
By Nicole Longo | March 29, 2019
Since the Department of Health and Human Services (HHS) released the Part B International Pricing Index (IPI) model late last year, there have been a number of inaccurate claims floating around...
Read More
OIG proposed rule could help strengthen the Part D market
By Holly Campbell | March 28, 2019
Patients should share in the $166B in rebates and discounts biopharmaceutical companies pay to insurance companies, the government, pharmacy benefit managers and other entities in the supply chain...
Read More
Medicare Monday (100)
340B Spotlight (40)
Cost & Consequence (0)
